Rasmus Tetens Hoeg, M.D. for UC Davis Health

Rasmus Tetens Hoeg, M.D.

Assistant Professor of Medicine

To see if Rasmus Tetens Hoeg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Bone Marrow Transplant


Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817

Get Directions

Phone: 916-734-5959

Additional Numbers

Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Hoeg believes in high quality, innovative, and compassionate care of his patients. Dr. Hoeg believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.

Clinical Interests

Dr. Hoegs’ clinical interests include: Bone Marrow Transplant and other hematologic malignancies.

Research/Academic Interests

Dr. Hoeg's research interest is in bone marrow transplant, myeloproliferative neoplasms and graft versus host disease.


Hematology and Oncology
Malignant Hematology/Cellular Therapy and Transplantation

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., History and English, University of Copenhagen, Copenhagen, Denmark 1998

Medical School

M.D., University of Copenhagen, Copenhaven, Denmark 2005


Internal Medicine, Gundersen Lutheran Medical Foundation, La Crosse WI 2008


Hematology, Herlev Hospital, Denmark, 2010-2011


Hematology/Oncology, Næstved Sygehus, Næstved, Denmark 2009-2010


Hematology/Oncology, Næstved Sygehus, Næstved, Denmark 2012-2013

To view a detailed list of Dr. Hoeg's publications, please click here.


Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.

Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Abedi M. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021 Sep 1;56:2975–2980. doi:10.1038/s41409-021-01444-1.

Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e611-e618. doi:10.1016/j.clml.2021.02.007. Epub 2021 Mar 2. PMID:33811007.

Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi:10.1002/ajh.26105. Epub 2021 Feb 26. PMID:33476436.

Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021 Mar 11;11:649209. doi:10.3389/fonc.2021.649209. PMID:33777810.

Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Hoeg R, Sun T, Keegan THM. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021 Jan 7;11(5). doi.org/10.1038/s41408-020-00400-4.

Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):453-458. doi:10.1016/j.clml.2020.02.006. Epub 2020 Feb 20. PMID:32171691.

Pham B, Hoeg R, Hariharana N, Alvarez K, Rosenberg AS, Jonas BA, Tuscano JM, Abedi M. Treatment with FLAG followed by second allogeneic stem cell transplant for relapsed acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2019;37(15_suppl):e18503-e18503. doi:10.1200/JCO.2019.37.15_suppl.e18503.

Raghavendra M, Hoeg RT, Bottner WA, Agger WA. Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care. WMJ. 2014 Apr;113(2):53-8. PMID:24908899.